Lung cancer is the leading cause of malignant
tumor-related deaths worldwide. The presence of tumor-initiating cells in
lung cancer leads to
tumor recurrence,
metastasis, and resistance to conventional treatment.
Cleavage and polyadenylation specificity factor 4 (CPSF4) activation in
tumor cells contributes to the poor prognosis of
lung cancer. However, the precise
biological functions and molecular mechanisms of CPSF4 in the regulation of tumor-initiating cells remain unclear. We demonstrated that CPSF4 promotes
tumor-initiating phenotype and confers chemoresistance to
paclitaxel both in vitro and in vivo. Mechanistically, we showed that CPSF4 binds to the promoters of
vascular endothelial growth factor (
VEGF) and
neuropilin-2 (NRP2) and activated their transcription. In addition, we showed that CPSF4/
VEGF/NRP2-mediated
tumor-initiating phenotype and chemoresistance through TAZ induction. Furthermore, analysis of clinical data revealed that
lung cancer patients with high CPSF4 expression exhibit high expression levels of
VEGF, NRP2, and TAZ and that expression of these
proteins are positively correlated with poor prognosis. Importantly, selective inhibition of
VEGF, NRP2, or TAZ markedly suppressed CPSF4-mediated
tumor-initiating phenotype and chemoresistance. Our findings reveal the mechanism of CPSF4 modulating
tumor-initiating phenotype and chemoresistance in
lung cancer and indicate that the CPSF4-VEGF-NRP2-TAZ signaling pathway may be a prognosis marker and therapeutic target in
lung cancer.